A Study of Anti-Cancer Therapies Targeting the MAPK Pathway in Patients With Advanced NSCLC (HERKULES-2)
A Phase 1b Master Protocol of Agents Targeting the Mitogen-Activated Protein Kinase Pathway in Patients With Advanced Non-Small-Cell Lung Cancer
Sponsor: Erasca, Inc.
This PHASE1 trial investigates Advanced Non-squamous Non-small-cell Lung Cancer and is currently completed. Erasca, Inc. leads this study, which shows 11 recorded versions since 2021 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
11 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1
-
Aug 2023 — Jul 2024 [monthly]
Completed PHASE1
Status: Active Not Recruiting → Completed
-
Mar 2023 — Aug 2023 [monthly]
Active Not Recruiting PHASE1
-
Feb 2023 — Mar 2023 [monthly]
Active Not Recruiting PHASE1
Status: Recruiting → Active Not Recruiting · Phase: PHASE1_PHASE2 → PHASE1
▶ Show 6 earlier versions
-
Sep 2022 — Feb 2023 [monthly]
Recruiting PHASE1_PHASE2
-
Apr 2022 — Sep 2022 [monthly]
Recruiting PHASE1_PHASE2
-
Feb 2022 — Apr 2022 [monthly]
Recruiting PHASE1_PHASE2
-
Jan 2022 — Feb 2022 [monthly]
Recruiting PHASE1_PHASE2
-
Oct 2021 — Jan 2022 [monthly]
Recruiting PHASE1_PHASE2
-
Sep 2021 — Oct 2021 [monthly]
Recruiting PHASE1_PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Erasca, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .